PL2066647T3 - Benzoksazole i oksazolopirydyny użyteczne jako inhibitory kinaz Janusa - Google Patents

Benzoksazole i oksazolopirydyny użyteczne jako inhibitory kinaz Janusa

Info

Publication number
PL2066647T3
PL2066647T3 PL07802300T PL07802300T PL2066647T3 PL 2066647 T3 PL2066647 T3 PL 2066647T3 PL 07802300 T PL07802300 T PL 07802300T PL 07802300 T PL07802300 T PL 07802300T PL 2066647 T3 PL2066647 T3 PL 2066647T3
Authority
PL
Poland
Prior art keywords
oxazolopyridines
benzoxazoles
useful
janus kinases
kinases inhibitors
Prior art date
Application number
PL07802300T
Other languages
English (en)
Inventor
Marc Gerspacher
Pascal Furet
Eric Vangrevelinghe
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37717673&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2066647(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PL2066647T3 publication Critical patent/PL2066647T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
PL07802300T 2006-09-15 2007-09-13 Benzoksazole i oksazolopirydyny użyteczne jako inhibitory kinaz Janusa PL2066647T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06120733A EP1900729A1 (en) 2006-09-15 2006-09-15 Benzoxazoles and oxazolopyridines being useful as Janus kinases inhibitors
EP07802300A EP2066647B1 (en) 2006-09-15 2007-09-13 Benzoxazoles and oxazolopyridines being useful as janus kinases inhibitors
PCT/EP2007/007983 WO2008031594A1 (en) 2006-09-15 2007-09-13 Benzoxazoles and oxazolopyridines being useful as janus kinases inhibitors

Publications (1)

Publication Number Publication Date
PL2066647T3 true PL2066647T3 (pl) 2012-04-30

Family

ID=37717673

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07802300T PL2066647T3 (pl) 2006-09-15 2007-09-13 Benzoksazole i oksazolopirydyny użyteczne jako inhibitory kinaz Janusa

Country Status (30)

Country Link
US (1) US8629168B2 (pl)
EP (2) EP1900729A1 (pl)
JP (1) JP5325105B2 (pl)
KR (1) KR20090064389A (pl)
CN (1) CN101516860B (pl)
AR (1) AR062786A1 (pl)
AT (1) ATE532774T1 (pl)
AU (1) AU2007296916B2 (pl)
BR (1) BRPI0716841A2 (pl)
CA (1) CA2660987A1 (pl)
CL (1) CL2007002669A1 (pl)
CO (1) CO6150142A2 (pl)
CR (1) CR10639A (pl)
EA (1) EA200900388A1 (pl)
ES (1) ES2377148T3 (pl)
GT (1) GT200900056A (pl)
IL (1) IL196860A0 (pl)
MA (1) MA30723B1 (pl)
MX (1) MX2009002812A (pl)
NO (1) NO20091469L (pl)
PA (1) PA8748101A1 (pl)
PE (1) PE20080842A1 (pl)
PL (1) PL2066647T3 (pl)
PT (1) PT2066647E (pl)
SM (1) SMP200900023B (pl)
TN (1) TN2009000070A1 (pl)
TW (1) TW200819444A (pl)
UY (1) UY30587A1 (pl)
WO (1) WO2008031594A1 (pl)
ZA (1) ZA200900477B (pl)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2467670B (en) 2007-10-04 2012-08-01 Intellikine Inc Chemical entities and therapeutic uses thereof
US8993580B2 (en) 2008-03-14 2015-03-31 Intellikine Llc Benzothiazole kinase inhibitors and methods of use
CN102124009B (zh) 2008-07-08 2014-07-23 因特利凯公司 激酶抑制剂及其使用方法
MX2011000211A (es) * 2008-07-15 2011-03-03 Sanofi Aventis Oxazolopirimidinas como agonistas del receptor edg-1.
WO2010018874A1 (en) * 2008-08-12 2010-02-18 Takeda Pharmaceutical Company Limited Amide compound
US8476282B2 (en) 2008-11-03 2013-07-02 Intellikine Llc Benzoxazole kinase inhibitors and methods of use
MX2011005621A (es) 2008-11-28 2011-06-20 Kowa Co Derivado de piridin-3-carboxiamida.
EP2518054A1 (en) 2009-12-24 2012-10-31 Takeda Pharmaceutical Company Limited Amide compound
TWI485153B (zh) * 2010-01-13 2015-05-21 Sanofi Aventis 2,5,7-經取代唑并嘧啶衍生物
TWI592411B (zh) 2011-02-23 2017-07-21 英特爾立秦有限責任公司 激酶抑制劑之組合及其用途
US8580816B2 (en) * 2011-07-07 2013-11-12 Sanofi Carboxylic acid derivatives having an oxazolo[5,4-b]pyridine ring
US8907093B2 (en) * 2011-07-07 2014-12-09 Sanofi Carboxylic acid derivatives having an oxazolo[4,5-c]pyridine ring
CN103102359B (zh) * 2011-11-15 2016-11-09 江苏先声药业有限公司 嘧啶类化合物及其应用
AU2012345732B2 (en) 2011-11-30 2016-07-14 Emory University Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections
WO2014075318A1 (zh) * 2012-11-19 2014-05-22 江苏先声药业有限公司 嘧啶类化合物及其应用
JP6360881B2 (ja) 2013-03-22 2018-07-18 ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. 触媒的mtorc1/2阻害薬及びオーロラaキナーゼの選択的阻害薬の組合せ
CN103664759A (zh) * 2013-12-06 2014-03-26 常熟市联创化学有限公司 一种3-羟基-2-硝基吡啶的制备方法
AU2015210638B2 (en) 2014-02-03 2017-07-20 Quadriga Biosciences, Inc. Beta-substituted beta-amino acids and analogs as chemotherapeutic agents
EP3102194A1 (en) 2014-02-03 2016-12-14 Quadriga Biosciences, Inc. Beta-substituted gamma-amino acids and analogs as chemotherapeutic agents
WO2016047678A1 (ja) * 2014-09-25 2016-03-31 武田薬品工業株式会社 複素環化合物
AR105592A1 (es) 2015-08-03 2017-10-18 Quadriga Biosciences Inc b-AMINOÁCIDOS b-SUSTITUIDOS Y ANÁLOGOS COMO AGENTES QUIMIOTERAPÉUTICOS Y USOS DE LOS MISMOS
WO2022251597A1 (en) 2021-05-28 2022-12-01 Verge Analytics, Inc. Methods of treating neurological disorders with modulators of ribosomal protein s6 kinase alpha-1 (rsk1) and ribosomal protein s6 kinase alpha-3 (rsk2)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP1905A (en) * 1999-12-10 2008-10-20 Pfizer Prod Inc Pyrrolo[2,3-d] Pyrimidine Compounds.
SE0301373D0 (sv) * 2003-05-09 2003-05-09 Astrazeneca Ab Novel compounds
DE10344223A1 (de) * 2003-09-24 2005-04-21 Merck Patent Gmbh 1,3-Benzoxazolylderivate als Kinase-Inhibitoren
GB0402140D0 (en) * 2004-01-30 2004-03-03 Smithkline Beecham Corp Novel compounds
EP1674467A1 (en) * 2004-12-22 2006-06-28 4Sc Ag 2,5- and 2,6-disubstituted benzazole derivatives useful as protein kinase inhibitors
CA2620127A1 (en) * 2005-09-02 2007-03-08 F. Hoffmann-La Roche Ag Benzooxazole, oxazolopyridine, benzothiazole and thiazolopyridine derivatives
EP2046759A1 (en) * 2006-07-21 2009-04-15 Novartis AG 2, 4 -di (arylaminio) -pyrimidine-5-carboxamide compounds as jak kinases inhibitors

Also Published As

Publication number Publication date
MA30723B1 (fr) 2009-09-01
MX2009002812A (es) 2009-03-31
ATE532774T1 (de) 2011-11-15
IL196860A0 (en) 2009-11-18
ES2377148T3 (es) 2012-03-22
TW200819444A (en) 2008-05-01
EP1900729A1 (en) 2008-03-19
US8629168B2 (en) 2014-01-14
WO2008031594A1 (en) 2008-03-20
AU2007296916B2 (en) 2011-10-06
EA200900388A1 (ru) 2009-08-28
EP2066647B1 (en) 2011-11-09
CN101516860A (zh) 2009-08-26
US20100009978A1 (en) 2010-01-14
PT2066647E (pt) 2012-01-17
CR10639A (es) 2009-07-03
NO20091469L (no) 2009-04-15
JP5325105B2 (ja) 2013-10-23
CO6150142A2 (es) 2010-04-20
PA8748101A1 (es) 2009-08-26
UY30587A1 (es) 2008-05-02
PE20080842A1 (es) 2008-08-11
EP2066647A1 (en) 2009-06-10
GT200900056A (es) 2011-11-08
AU2007296916A1 (en) 2008-03-20
CA2660987A1 (en) 2008-03-20
BRPI0716841A2 (pt) 2013-10-01
TN2009000070A1 (en) 2010-08-19
SMAP200900023A (it) 2009-05-11
KR20090064389A (ko) 2009-06-18
AR062786A1 (es) 2008-12-03
CN101516860B (zh) 2012-06-27
CL2007002669A1 (es) 2008-05-09
ZA200900477B (en) 2010-01-27
SMP200900023B (it) 2009-07-14
JP2010503629A (ja) 2010-02-04

Similar Documents

Publication Publication Date Title
IL196860A0 (en) Benzoxazoles and oxazolopyridines being useful as janus kinases inhibitors
HUS2200052I1 (hu) Imidazotriazinok és imidazopirimidinek mint kinázgátlók
ZA200808536B (en) Deazapurines useful as inhibitors of janus kinases
ZA201004055B (en) 4-pyrazolyl-n-arylpyrimidin-2-amines and 4-pyrazolyl-n-heteroarylpyrimidin-2-amines as janus kinase inhibitors
EP2166846A4 (en) INHIBITORS OF JANUS KINASES
EP2231143A4 (en) INHIBITORS OF JANUS KINASES
ZA200805053B (en) Azaindoles useful as inhibitors of janus kinases
ZA200802685B (en) Deazapurines useful as inhibitors of janus kinases
EP2278969A4 (en) INHIBITORS OF JANUS KINASES
EP2299816A4 (en) INHIBITORS OF JANUS KINASES
IL192634A0 (en) Thiazoles as 11 beta-hsd1 inhibitors
GB0619753D0 (en) Enzyme inhibitors
IL194339A0 (en) Enzyme inhibitors
EP2310384A4 (en) INHIBITORS OF KINASES JANUS
EP2200612A4 (en) JANUS KINASE INHIBITORS
HK1137756A1 (en) Substituted dihydropyrazolones and use thereof as hif-prolyl-4 -hydroxylase inhibitors hif--4-
EP2032141A4 (en) INHIBITORS OF KINASES JANUS
EP2341775A4 (en) INHIBITORS OF JANUS KINASES
GB0617161D0 (en) Enzyme inhibitors
ZA200808237B (en) Enzyme inhibitors
GB0620884D0 (en) Enzyme inhibitors
GB0624958D0 (en) Enzyme inhibitors